Global
Our Story

Share the latest information

Our Story
News
2023-12-19
Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan
On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.
More
2019-10-10
Report on the 29th ERS (European Respiratory Society Annual Conference) Conference of Loki Biology
From September 28 to October 2, 2019, the 29th ERS (European Respiratory Society Annual Conference) was held in Madrid, Spain. More than 20000 colleagues from all over the world participated in the event. This ERS meeting covered the key topics of respiratory medicine in 14 scientific fields, including tuberculosis, lung cancer, chronic and acute respiratory failure, sleep disordered breathing, interstitial lung disease, pneumonia, cystic fibrosis, COPD and asthma.
More
2019-07-27
Don't forget your original intention and move forward courageously -- and Loqi 2019 Mid-Year Summary and Commendation Conference
On July 26, the 2019 Mid-Year Work Summary Meeting of Luoqi Biology was held in the Phase III Exhibition Center of Shanghai International Medical Park. All staff of the company attended the meeting, which was presided over by Zhu Min, assistant general manager.
More
2019-04-11
New drug progress I LQ036, the world's first inhaled nano-antibody drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
On April 11, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. won the bid for the 2019 "Science and Technology Innovation Action Plan" in the field of biomedicine science and technology support project in Shanghai.
More
2019-04-11
Good news - Luoqi Biotechnology won the bid for the 2019 "Science and Technology Innovation Action Plan" in the biomedical science and technology support project in Shanghai
On March 1, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. and Zhejiang Terex Pharmaceutical Co., Ltd. signed a global strategic cooperation agreement, announcing that the two sides will carry out cooperation in various aspects in the field of tumor immunotherapy and nano-antibody drugs, with strong cooperation, complementary advantages and win-win cooperation. Dr. Wan Yakun, chairman of Rocky Biology, and Dr. Wu Youling, chief executive officer and chairman of Trisys Pharmaceutical attended the ceremony and signed. Xiong Quanlong, deputy director of the Standing Committee of Huzhou Municipal People's Congress and secretary of the Party Committee of the Development Zone, attended the ceremony and delivered an important speech.
More
2018-10-31
[Good news] Luoqi Biology won the winner of the 2018 "Entrepreneurship in Shanghai" International Innovation and Entrepreneurship Competition
On October 30, Luoqi Biology was invited to participate in the "Opening Ceremony of the 8th China Innovation and Entrepreneurship Competition (Shanghai) and 2019 Entrepreneurship in Shanghai International Innovation and Entrepreneurship Competition". At the ceremony, relevant leaders presented awards to the winners of the 2018 "Entrepreneurship in Shanghai" International Innovation and Entrepreneurship Competition.
More
2018-10-17
Loki Biological Thanksgiving has you all the way
From October 16, 2017 to October 16, 2018, the first anniversary of the founding of Rocky Biology! We are a group of young partners who are deeply engaged in the field of antibody drugs. This year, we have been moving forward, and this year, we have gained a lot!
More
Total 46 12345